AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:53:00Z
Why Tempus AI Stock Skyrocketed Nearly 22% Today
Wed 21 Aug 24, 10:13 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -113.27500M | -65.21200M | -41.22300M | -25.07500M | -19.87900M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | -113.31500M | -65.22600M | -41.28000M | -25.08400M | -19.88600M |
| Selling general administrative | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13.35M | 31.66M | 20.11M | 22.08M | 11.80M |
| Reconciled depreciation | 8.43M | 6.01M | 5.76M | 4.75M | 3.07M |
| Ebit | -115.53100M | -65.35300M | -42.14600M | -22.41800M | -13.51000M |
| Ebitda | -113.07400M | -65.02800M | -35.46300M | -22.23800M | -10.44400M |
| Depreciation and amortization | 2.46M | 0.33M | 6.68M | 0.18M | 3.07M |
| Non operating income net other | 2.46M | 0.33M | 0.93M | - | - |
| Operating income | -115.53100M | -65.35300M | -42.14600M | -22.41800M | -13.77000M |
| Other operating expenses | 180.58M | 150.85M | 120.79M | 87.62M | 51.54M |
| Interest expense | 0.20M | 0.18M | 0.00200M | 1.13M | 1.89M |
| Tax provision | 0.04M | 0.01M | 0.06M | 0.00900M | 0.00700M |
| Interest income | 2.40M | 0.37M | 0.95M | 1.62M | 0.29M |
| Net interest income | 2.19M | 0.18M | 0.95M | 0.49M | -1.60100M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 0.04M | 0.01M | 0.06M | 0.00900M | 0.00700M |
| Total revenue | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M |
| Total operating expenses | 128.88M | 97.01M | 62.26M | 44.50M | 25.57M |
| Cost of revenue | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M |
| Total other income expense net | 2.26M | 0.14M | 0.92M | -2.65700M | -4.50800M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | -113.31500M | -65.22600M | -41.28000M | -25.08400M | -19.88600M |
| Net income applicable to common shares | -113.31500M | -65.22600M | -41.28000M | -25.08400M | -19.88600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 225.10M | 292.70M | 396.53M | 244.84M | 157.29M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.36M | 6.81M | 7.09M | 5.44M | 3.38M |
| Total liab | 95.66M | 74.56M | 86.23M | 49.90M | 50.60M |
| Total stockholder equity | 129.44M | 218.14M | 310.30M | 194.94M | 106.69M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 19.62M | 11.40M | 12.58M | 8.86M | 5.29M |
| Common stock | 0.00500M | 0.00500M | 0.00400M | 0.00400M | 0.00300M |
| Capital stock | 0.00500M | 0.00500M | 0.00400M | 0.00400M | 0.00300M |
| Retained earnings | -468.70600M | -360.41000M | -247.09500M | -181.86900M | -140.58900M |
| Other liab | - | 0.01M | 2.12M | 0.72M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 4.59M | 4.83M | 12.29M | 1.76M |
| Cash | 56.98M | 89.13M | 105.58M | 68.53M | 55.05M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 47.23M | 33.13M | 31.31M | 40.64M | 49.96M |
| Current deferred revenue | 3.29M | 1.26M | 3.98M | 21.03M | 35.98M |
| Net debt | -8.02200M | -40.47800M | -52.78800M | -57.53900M | -53.68500M |
| Short term debt | 9.41M | 7.61M | 5.53M | 2.44M | 1.36M |
| Short long term debt | 1.65M | 2.22M | 1.81M | - | - |
| Short long term debt total | 48.96M | 48.65M | 52.80M | 10.99M | 1.36M |
| Other stockholder equity | 598.36M | 579.46M | 557.56M | 376.79M | 89.99M |
| Property plant equipment | - | 61.94M | 19.65M | 11.83M | 15.95M |
| Total current assets | 141.93M | 199.70M | 318.23M | 220.72M | 139.58M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 218.14M | 310.30M | 194.94M | 106.69M |
| Short term investments | 57.20M | 78.53M | 181.48M | 134.76M | 73.24M |
| Net receivables | 17.73M | 16.64M | 18.47M | 6.35M | 3.30M |
| Long term debt | - | - | - | - | - |
| Inventory | 5.66M | 8.59M | 5.61M | 2.67M | 4.61M |
| Accounts payable | 14.92M | 12.85M | 9.22M | 8.30M | 7.34M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.22200M | -0.91200M | -0.16600M | 0.02M | -0.00600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00500M | 0.00400M | 0.00400M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -360.41000M | -247.09500M | -181.86900M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 6.16M | 4.59M | 4.83M | 2.02M | 1.76M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 83.17M | 93.00M | 78.30M | 24.12M | 17.71M |
| Capital lease obligations | 46.08M | 46.43M | 52.80M | 10.99M | 2.00M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 102.43M | -48.98600M | -61.89700M | -73.19700M | -73.19700M |
| Change to liabilities | 1.19M | 1.62M | 5.00M | -5.52200M | 20.37M |
| Total cashflows from investing activities | 52.54M | -60.06900M | -65.14300M | -81.57900M | -7.85200M |
| Net borrowings | -1.09900M | 3.31M | 3.31M | -5.00000M | -0.64500M |
| Total cash from financing activities | 1.37M | 169.70M | 121.27M | 134.95M | -0.59100M |
| Change to operating activities | 11.40M | -0.54600M | 1.09M | -1.63600M | -0.36700M |
| Net income | -113.31500M | -65.22600M | -41.28000M | -25.08400M | -19.88600M |
| Change in cash | -16.45700M | 38.85M | 13.48M | 35.30M | -2.87300M |
| Begin period cash flow | 107.38M | 68.53M | 55.05M | 19.74M | 22.62M |
| End period cash flow | 90.92M | 107.38M | 68.53M | 55.05M | 19.74M |
| Total cash from operating activities | -70.23300M | -70.82800M | -42.65300M | -18.06900M | 5.57M |
| Issuance of capital stock | 0.00000M | 162.26M | 117.50M | 144.71M | - |
| Depreciation | 8.43M | 6.01M | 5.76M | 4.75M | 3.07M |
| Other cashflows from investing activities | - | - | - | -73.19700M | 0.00000M |
| Dividends paid | - | - | - | - | 0.00000M |
| Change to inventory | -2.98200M | 0.03M | -1.07600M | -1.17400M | -2.06800M |
| Change to account receivables | 1.82M | -12.11800M | -3.04900M | 1.07M | -2.51900M |
| Sale purchase of stock | 2.46M | 166.39M | 121.27M | 145.42M | 0.08M |
| Other cashflows from financing activities | 3.66M | 9.30M | 3.77M | 15.24M | 0.05M |
| Change to netincome | 19.54M | 14.55M | 8.30M | 9.53M | 6.97M |
| Capital expenditures | 49.90M | 11.08M | 3.25M | 8.38M | 7.85M |
| Change receivables | 1.82M | -12.11800M | -3.04900M | - | - |
| Cash flows other operating | 12.10M | -15.66200M | -17.38000M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -16.33000M | 38.80M | 13.47M | - | - |
| Change in working capital | 10.61M | -31.14400M | -17.22900M | -7.26300M | 15.42M |
| Stock based compensation | 19.43M | 14.38M | 8.24M | 4.86M | 1.32M |
| Other non cash items | 4.61M | 3.12M | 1.47M | 1.56M | 1.18M |
| Free cash flow | -120.12900M | -81.91100M | -45.89900M | -26.45100M | -2.28000M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PSNL Personalis Inc |
1.27 35.67% | 4.83 | - | - | 0.89 | 0.50 | 0.05 | 0.01 |
| TMO Thermo Fisher Scientific Inc |
2.81 0.54% | 518.99 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.38 0.17% | 227.92 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-0.4 0.10% | 410.36 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
-0.225 0.12% | 190.75 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
6600 Dumbarton Circle, Fremont, CA, United States, 94555
| Name | Title | Year Born |
|---|---|---|
| Mr. John Stephen West | Co-Founder, CEO, Pres & Director | 1957 |
| Mr. Aaron L. Tachibana | Sr. VP & CFO | 1961 |
| Dr. Richard Chen M.D., M.S., MS | Sr. VP of R&D and Chief Medical Officer | 1971 |
| Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
| Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 1972 |
| Dr. Atul Butte | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
| Dr. Michael Snyder Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
| Ms. Carol J. Tillis | VP of Fin. & Admin. | NA |
| Mr. Stephen M. Moore J.D. | VP, Gen. Counsel & Corp. Sec. | 1972 |
| Mr. Michael J Fitzpatrick | VP of Worldwide Sales | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...